Ligand Pharma (LGND) Tops Q4 EPS by 9c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $318.78 --0%
EPS Growth %: -25.6%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
CCB, ESCA, MPT, More
EPS Growth %: -25.6%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
CCB, ESCA, MPT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.27, $0.09 better than the analyst estimate of $1.18. Revenue for the quarter came in at $42.81 million versus the consensus estimate of $39.03 million.
GUIDANCE:
Ligand Pharma sees FY2025 EPS of $6.00-$6.25, versus the consensus of $6.14. Ligand Pharma sees FY2025 revenue of $180-200 million, versus the consensus of $188.8 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Linde (LIN) Tops Q3 EPS by 7c ; Offers Guidance
- Shell plc (SHEL) Tops Q3 EPS by 47c
- Mizuho Starts Castle Biosciences (CSTL) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
